Showing 51–75 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Lopes SR, Marçal M, Fernandes N, Silva F, Barbosa P, et al.
…nes in 2022, on the safety and efficacy of existing and new regimens for drug-susceptible TB (DS-TB) and DR-TB in adults and children. Methods A comprehensive search was performed across three databases for studies published between January 2022 and February 2024, focusing on cur…
Pettit AC, Phillips PPJ, Kurbatova E, Vernon A, Nahid P, et al.
…% to +22.4%]). Fewer AEs were reported in rifapentine-based regimens (15%) than the control regimen (21%). Conclusions In people with HIV-associated DS-PTB with CD4+ counts ≥100 cells/μL on efavirenz-based ART, the 4-month daily rifapentine-moxifloxacin regimen was noninferior to…
Malik AA, Farooq S, Jaswal M, Khan H, Nasir K, et al.
Background Shorter regimens for tuberculosis prevention can improve completion rates and protection against developing active tuberculosis disease after tuberculosis exposure. We aimed to assess the safety and feasibility of 1 month of daily isoniazid and rifapentine (1HP) in chi…
Dorman SE, Nahid P, Kurbatova EV, Goldberg SV, Bozeman L, et al.
…trials of tuberculosis treatment have shown that once-daily regimens in which rifampin is replaced by high dose rifapentine have potent antimicrobial activity that may be sufficient to shorten overall treatment duration. Herein we describe the design of an ongoing phase 3 clinica…
Marcela Muñóz-Torrico, Norma A. Téllez-Navarrete, Heinke Kunst, Linh Nguyen
…nd when to start anti-TB treatment, discuss the recommended regimens for drug sensitive TB. Establish recommended doses of the primary regimen, and finally recommended treatment adjustment in special situations. Effective and on time tuberculosis treatment is essential for TB con…
Ying Liu, Zixuan Cui, Yingxi Fu, Edward D Chan, Chunmei Hu
…ontezolid could be a valuable addition to anti-TB treatment regimens.
Perlman D, El-Sadr W
…icity, survival, and development of resistance in these two regimens. ORIGINAL: To compare the efficacy and safety of induction and continuation therapies for the treatment of pulmonary TB in HIV-infected patients who are either from areas with known high rates of resistance to …
Amira Mahmood, Mohammad Bilal Ashfaq, Catherine Drain, Eoin Melby, Michael Hunter, et al.
…gies: there is now a surge in novel tuberculosis agents and regimens entering human trials. For decades, drug resistant tuberculosis required at least 18 months of second line and third line combination treatments that included injectable agents. In 2022, in response to a growing…
Ying Li, Zhenzhou Feng, Linlin Song, S. Feng, Z. Wenhong
…en conducted to evaluate the safety and efficacy of shorter regimens of different doses of rifapentine for DS-TB. Design/Methods: In stage 1 of this phase II/III, multicenter, open-label trial, a total of 400 participants with DS-TB were randomly assigned to receive either the st…
Ekaterina M. Petrunina, Sergey Skornyakov
…d. Indications for elective surgery, selection of treatment regimens and evaluation of their effectiveness were conducted in accordance with national Clinical Guidelines. MTB isolates from resected lung tissue were tested for phenotypic drug susceptibility and screened for resist…
Elias Jabbour, Marcia Pinto, Ricardo E Steffen, Fernanda Dockhorn, Daniele M Pelissari, et al.
…both children and adults, costs of newer, 6-month treatment regimens for rifampin-resistant tuberculosis (RR-TB) were less expensive than 18-month regimens. In children, the cost was US$4807 ($1559-$10 066) for the 6-month regimen and US$9212 ($2756-$19 567) for the 18-month regi…
Imazu P, Santos JM, Beraldi-Magalhães F, Fernandez-Llimos F, Tonin FS, et al.
… the comparative efficacy and safety of antimicrobial drugs regimens for treating pulmonary drug-susceptible tuberculosis (DS-TB). Methods A systematic review was performed with searches in PubMed and Scopus (PROSPERO-CRD42019141463). We included randomised controlled trials comp…
Shenzhen Third People's Hospital
Tuberculosis (TB) remains a major public health issue and one of the top ten causes of death from a single infectious disease worldwide. China is among the countries with the highest TB burden, ranking third globally for total TB cases and second for drug-resistant TB cases. PAN-…
Chihota V, Gombe M, Gupta A, Salazar-Austin N, Ryckman T, et al.
…alth Organization-recommended TB preventive treatment (TPT) regimens are available for all ages and for both drug-susceptible and drug-resistant TB infection. All regimens are generally safe, efficacious, and cost effective and have a low risk of generating resistance. TPT is rec…
Katarina Niward, MD, PhD
Tuberculosis (TB) treatment is long and complex with the risk of poor treatment adherence and treatment failure. Several attempts to shorten treatment of drug-susceptible TB have been unsuccessful. However, recent data support a shortened regimen for mild and moderate pulmonary T…
Jiwon Lyu, Tae Sun Shim
The most important thing for the management of drug susceptible pulmonary tuberculosis is to diagnose active pulmonary tuberculosis as soon as possible and prevent the occurrence of new patients through appropriate treatment. Therefore, it should be a priority to quickly detect t…
M. I. Romanova, E. V. Vаniev, D. O. Churkin, A. V. Abramchenko, А. I. Gayda, et al.
The article describes a clinical case of chemotherapy for drug susceptible rapidly progressive pulmonary tuberculosis in a patient with systemic lupus erythematosus taking glucocorticosteroids on regular basis. Due to adverse events that occurred when using the regimen of first l…
Adithya Cattamanchi, MD
…suboptimal, limiting the ability to assess new TB treatment regimens effectively. Identifying accurate sputum- or blood-based biomarkers for recurrence risk could significantly improve the efficiency and informativeness of Phase 2 and 3 clinical trials. The Candidate Clinical Co…
Eric Nuermberger, MD
A seamless, staged Phase II/III, open-label, multicenter, non-inferiority trial, to compare the efficacy and safety of 4 weeks of bedaquiline (BDQ) versus a a standard regimen for preventing regimen for preventing confirmed or probable tuberculosis disease (TBD) during 72 weeks o…
Kim HJ, Lee YJ, Song MJ, Kwon BS, Kim YW, et al.
Rifampicin is an important agent for tuberculosis treatment; however, it is often discontinued because of adverse reactions. The treatment regimen then can be administered as that for rifampicin-resistant tuberculosis, which can be toxic. We retrospectively reviewed 114 patients …
Rhastin A D Castro, Amanda Ross, Lujeko Kamwela, Miriam Reinhard, Chloé Loiseau, et al.
…quinolones (FQ) form the backbone in experimental treatment regimens against drug-susceptible tuberculosis. However, little is known on whether the genetic variation present in natural populations of Mycobacterium tuberculosis ( Mtb ) affects the evolution of FQ-resistance (FQ-R)…
Padmapriyadarsini C, Bhavani PK, Natrajan M, Ponnuraja C, Kumar H, et al.
…atients suffering from the disease. Besides newer drugs and regimens, other modalities like host-directed therapy are also being suggested to reach this goal. This study's objective is to assess the efficacy and safety of metformin-containing anti-TB treatment (ATT) regimen in co…
Mahmoud Tareq Abdelwahab, Elin M Svensson, Andreas H Diacon, Almarie Conradie, Morounfolu Olugbosi, et al.
…and clofazimine (CFZ), key drugs in current DR-TB treatment regimens. All of those prolong the QT interval. We aimed to describe this interaction to predict possible toxicities with established and novel dosing regimens to identify patients at higher risk of QT prolongation. The …
Zhang P, Shi H, Xie Y, Liang J, Hu Q, et al.
…f two different treatment durations (6-month versus 9-month regimens) regimen for patients with drug-susceptible pulmonary tuberculosis (DS-PTB) and concurrent type 2 diabetes (DM). Methods Patients with DS-PTB and type-2 DM from 22 hospitals in China are enrolled. They are rando…
Agathe Béranger, Belén P Solans, Ryo Miyakawa, Helen McIlleron, Joel Tarning, et al.
… attain our pharmacological target for all children, dosing regimens could be adjusted on NAT2 genotype and nutritional status.